Reading the offer · 15 company examples
FDA Letters About Generic and Brand-Name Claims
What the product name does—and does not—tell you
A name in a product listing can carry the same implication as a sentence in an advertisement. These letters address names and descriptions that present compounded medication alongside a brand, as its generic version, or as though the names were interchangeable.
For a shopper, the key question is what the quoted price actually purchases. A familiar brand inside parentheses does not establish that the prescription dispensed will be that approved branded product. Compare the medication description and dispensing details before comparing the dollar amounts.
The examples are not identical: some use “generic,” some put a brand in a product title, and some use “similar.” Read the cited passage and FDA’s stated concern together rather than treating every wording choice as the same claim.
An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.
This guide was organized in October 2026. Each company’s source-check date below is kept separately; the guide date does not mean its letter status was checked again.
All American Wellness
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The two cited claims are the only possessive ones in this collection: "Mounjaro's compounded version- Tirzepatide Prescription" and "Ozempic's compounded version- Semaglutide". Every other seller compares its product to a brand; this one attributes the product to the brand, as though Eli Lilly and Novo Nordisk each issued a compounded edition. FDA's conclusion was the wave's standard one — "Your claims imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
An apostrophe is doing something here that "same active ingredient as" never does. To say a product is Mounjaro's compounded version is not to compare two things — it is to say the brand HAS one, and that this is it. Read that way, the buyer is not choosing an alternative to the approved drug; they are choosing a variant of it, offered at a lower price, presumably by arrangement. No such arrangement exists. Neither Eli Lilly nor Novo Nordisk issues a compounded edition of anything, and a compounded product is prepared by a third-party pharmacy that the brand has no relationship with, does not supervise and did not test. That is the whole gap the possessive closes for free, which is why it is worth flagging separately from the ordinary equivalence claim: it does not overstate a similarity, it invents a lineage. The practical check is to ask who the seller says makes the product, and then to notice whether the answer is a company you could look up — a named pharmacy with a state license — or a brand that has been borrowed. Nothing in the letter concerns quality, contents or manufacturing, and FDA has not closed it out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [All American Wellness' website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website:
• “Mounjaro’s compounded version- Tirzepatide Prescription” • “Ozempic’s compounded version- Semaglutide”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
All American Wellness' website returned a live site on 2026-08-09 titled "All American Wellness | Health & Wellness Center in Fishers", presenting an Indiana bricks-and-mortar practice — "All American Wellness Weightloss & Hormone Therapy Services, Cicero, Indiana" — with a published phone number (317) 922-7298, a booking flow, a prescriptions section and a notice that "All prescription refills need to be placed when you take your third shot." That is a check of whether the site is up and what it says; it is not a check of anything the letter alleges.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Biopreventative
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited exactly one claim, and it is a definition: "Tadalafil (commonly known as Cialis) is a compound medication." No efficacy is asserted, no saving is promised and no comparison is drawn between two products — the brand name appears only as what the molecule is "commonly known as". FDA nonetheless held that "Your claim implies that your products are the same as an FDA-approved product when they are not", and concluded the compounded tadalafil products are misbranded under sections 502(a) and 502(bb). The letter names no other drug and makes no label finding.
What it means for the offer
This is the low-water mark of the letters we cover, and that is exactly what makes it worth reading. "Tadalafil (commonly known as Cialis) is a compound medication" is the sort of sentence a careful writer produces when trying to be helpful — it names the molecule, says plainly that the product is compounded, and adds the brand only so a reader knows what drug is being discussed. FDA still cited it. Set against the rest of this dataset, where sellers wrote "generic Ozempic" and invented approval dates, it establishes where the line actually sits: not at exaggeration, but at any construction that lets a compounded product borrow an approved product's name. Two practical points follow. First, the presence of a warning letter tells you nothing on its own about how strong the underlying claim was — the letters collected here range from a definition to a fabricated approval history, and they all look identical in a list. Second, this is the only tadalafil-only letter here, a useful reminder that the same rule governs erectile-dysfunction compounding as governs GLP-1s, even though the GLP-1 letters get the attention. Nothing in the letter concerns dosing, sourcing, or safety.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Biopreventative's website] in August 2025 and has observed that your website offers various compounded drug products, including tadalafil. As described below, your claim concerning your compounded tadalafil products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claim concerning your compounded tadalafil products appears on your website:
“Tadalafil (commonly known as Cialis) is a compound medication.”
Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Biopreventative's website was live in August 2026, titled "Bio Preventative", advertising "NEW PATIENTS GET $100 OFF FIRST MONTH PURCHASE" with semaglutide and tirzepatide weight-loss pages, a states-we-service page and a working contact form — an operating seller. Neither "tadalafil" nor "Cialis" appears on the homepage; we did not re-check the cited page beyond that.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Canada Med Stop
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted three short claims rather than full sentences: "The same active ingredient in branded weight loss medications.", "FDA-Approved Medication" and "GENERIC". Its conclusion is that "Compounded drug products are not FDA-approved" and that "Your claims imply that your products are the same as an FDA-approved product when they are not." Because the recipient is in Canada, the letter also carries an operative closing paragraph FDA applies to sellers outside the United States: products that appear to be misbranded "may be detained or refused admission", and FDA may advise regulators in the country from which the seller operates.
What it means for the offer
The word to stop on here is "GENERIC". A generic drug is a specific legal category: a copy approved by FDA after showing it performs the same as the original. A compounded drug is not that and cannot be, because no application was ever filed or approved for it. Putting the word on a compounded product borrows the one piece of reassurance that lets shoppers buy an unfamiliar cheaper version without a second thought, and "FDA-Approved Medication" beside it does the same job twice. The cross-border angle is the other half of what makes this letter practical. The closing paragraph about detention and refusal of admission is not decoration in a letter to a Canadian seller: a package that never clears the border is money spent for nothing, and that is a purchasing risk a domestic order does not carry. None of that makes the medication unsafe, and FDA does not say it is. It does mean two of the three phrases used to justify the price described a regulatory status the product never had.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Canada Med Stop's website] in August 2025 and has observed that your website offers compounded semaglutide drug products. As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claims concerning compounded semaglutide products appear on your website: • “The same active ingredient in branded weight loss medications.” • “FDA-Approved Medication” • “GENERIC”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.
Canada Med Stop's website returned a live site on 2026-08-09 titled "Canadian Pharmacy - Canada Med Stop", with an ordering flow, account login and refill system, and "Ozempic (Semaglutide)" listed among its top medications — an operating storefront.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Cosmo Med Spa
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The two claims FDA quoted are product listings, not marketing prose: "Ozempic (semaglutide) injection (4 weeks supply)" and "Ozempic (semaglutide) injection (10 weeks supply)" — the brand name in the product title, the molecule in a parenthesis, and the quantity expressed as a stretch of time. FDA's conclusion is the standard one, that "Compounded drug products are not FDA-approved" and the claim "implies that your products are the same as an FDA-approved product when they are not." The letter also carries FDA's non-US paragraph, warning that products "may be detained or refused admission" and that FDA may advise "the appropriate regulatory officials in the country from which you operate".
What it means for the offer
The unit of sale is the thing to look at here. "Ozempic (semaglutide) injection (4 weeks supply)" prices a brand-name drug by how long it lasts, which is exactly how a compounded vial is normally sold and exactly how an approved pen is not — a pen is sold by strength and pen count, because the dose you titrate up to changes how long one lasts. So the listing quietly promised a fixed duration for a drug whose duration depends on your dose, under a brand name that was not what would arrive. When a page prices medication in weeks, the question that follows is always "weeks at what dose", and there is no way to answer it from a title alone. The second thing worth knowing is jurisdictional. This recipient is in Ontario, and FDA's letter includes the paragraph it reserves for sellers outside the country: products may be detained at the border, and FDA may notify the regulator where the seller operates. For a buyer, that is not a safety warning — it is a delivery risk, and a quiet reminder that a site can be a foreign business even when its checkout is in dollars and its copy names US brands. The domain FDA reviewed now redirects to a Markham spa storefront that no longer lists the medication at all.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Cosmo Med Spa's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide. As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
“Ozempic (semaglutide) injection (4 weeks supply)”
“Ozempic (semaglutide) injection (10 weeks supply)”
Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.
In August 2026 Cosmo Med Spa's website, the one FDA reviewed, sent visitors on to Cosmo Spa Markham's website, a live storefront titled "Products | Cosmo Spa Markham" selling skincare brands, injectables and IV therapy with working prices and cart. The business is operating; the cited Ozempic listings no longer appear in its products.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Expert Aesthetics
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Two claims were quoted, and both are sales copy rather than product labels: "At home weight loss with the popular Ozempic generic Semaglutide." and "At home weight loss with the popular Mounjaro generic Tirzepatide." The regulated words — "Ozempic generic Semaglutide" — sit inside a sentence about convenience and popularity, not inside a product title. FDA's conclusion was the standard one for this round of FDA letters: "Your claims imply that your products are the same as an FDA-approved product when they are not." The letter was addressed to the clinic's named owner, "Ms. Burr".
What it means for the offer
"The popular Ozempic generic Semaglutide" is a phrase that does three things at once, and only one of them is a claim you can argue with. It flags demand — other people are buying this. It supplies a familiar landmark — Ozempic. And in the middle it slips in the word "generic", which is the only regulated term in the sentence and the only one that is wrong: a generic is an FDA-approved copy of an approved drug, held to the original's standards, and a compounded product is not one. Wrapped in a sentence about at-home convenience it reads as a description of a category rather than an assertion about a product, which is exactly why it is worth pausing on. The other useful detail is who received the letter. FDA addressed it to a named nurse-owner at a Texas clinic that has been trading for over a decade, not to a numbered LLC behind a checkout page — a reminder that this kind of letter is about the words on a website, and that established, accountable, locally-run practices receive them too. Nothing in the letter concerns how these products were made or what was in them. FDA made no finding on quality, and has not closed the letter out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Expert Aesthetics' website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website:
• “At home weight loss with the popular Ozempic generic Semaglutide.”
• “At home weight loss with the popular Mounjaro generic Tirzepatide.”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Expert Aesthetics' website returned a live site on 2026-08-09 titled "Brenda Burr | Expert Aesthetics-Erasing Age | United States", running a banner reading "Celebrating 12 years of business", with a Weight Loss/Peptides section, an online store, gift cards, payment options and online booking. That is a check of whether the site is up and who it names; it is not a check of anything the letter alleges.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Get Fit Medical
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited four claims at once, covering four molecules in two unrelated categories, each written to the same template: "SILDENAFIL (GENERIC VIAGRA)", "TADALAFIL (GENERIC CIALIS)", "SEMAGLUTIDE (GENERIC OZEMPIC/WEGOVY)" and "TIRZEPATIDE (GENERIC MOUNJARO)". FDA framed them with a qualifier used in no other letter we cover — the claims "appear on webpages that offer only compounded products" — and concluded that "Your claims imply that your products are the same as an FDA-approved product when they are not." There is no label finding and no separate efficacy finding; the whole letter is those four bracketed words.
What it means for the offer
Four products, two categories, one template — and that is the point. This site was not making an argument about semaglutide; it was applying a formatting rule, "MOLECULE (GENERIC BRAND)", to everything on the shelf. Whoever built those pages appears to have treated "generic" as the ordinary retail word for a cheaper version of a familiar drug, which is how it works at a pharmacy counter and is not how it works here: a generic is an FDA-approved copy of an approved drug, and none of these four had one. Sildenafil and tadalafil are the interesting case, because generic sildenafil and generic tadalafil genuinely exist as approved products — so the same phrase is accurate at a pharmacy and inaccurate on a page that ships compounded material. That is a distinction a shopper comparing prices has almost no way to see, and it is why the price gap between a "generic" at a pharmacy and a "generic" on a telehealth storefront can be so wide. FDA's qualifier does the work: the pages in question "offer only compounded products", so nothing on them could have been the generic the label promised. The site itself is no longer reachable — its Squarespace subscription has expired.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Get Fit Medical's website] in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide. As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products: • “SILDENAFIL (GENERIC VIAGRA)” • “TADALAFIL (GENERIC CIALIS)” • “SEMAGLUTIDE (GENERIC OZEMPIC/WEGOVY)” • “TIRZEPATIDE (GENERIC MOUNJARO)”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Get Fit Medical's website showed only a "Squarespace - Website Expired" page in August 2026 — the hosting subscription has lapsed, so no storefront is reachable. An expired website plan is not evidence a business has closed: it can be renewed, and a company can move platforms. Recorded as unknown rather than ceased-operations.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
The HCG Institute
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA quoted three claims. The first is an efficacy list — "Clinically proven to reduce appetite, lower food cravings, improve food intake regulation and glycemic control." The second invents a credential: "Compounded Generic Semaglutide is a revolutionary FDA-inspected medication for rapid weight loss that is given once weekly." The third is an argument rather than a slogan, acknowledging that "due to American drug marketing, many people only know of semaglutide either as ‘a GLP-1’ or ‘Ozempic’" before concluding that "‘Generic’ or compounded semaglutide, like what we sell here at the HCG Institute, are the same medication, as well." FDA held that the claims "imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
"FDA-inspected" is the phrase to take away from this one. It is not a thing a medication can be. FDA inspects facilities — it registers and inspects outsourcing facilities and, at times, pharmacies — and it approves drugs; there is no inspection that a compounded vial passes and is then labeled with. The phrase works precisely because it sounds like a lesser, more modest version of "FDA-approved", which makes it read as honest restraint rather than as a claim. The same letter shows why that matters: the third quoted passage is a small essay about how American drug marketing teaches people to say "Ozempic" when they mean semaglutide — an accurate observation — and it ends by telling the reader the compounded version is "the same medication, as well". Naming the confusion and then trading on it is a more sophisticated move than any of the one-line claims elsewhere in these letters. For anyone comparing prices, the operative rule is simple: a compounded product has no FDA status to cite, so any phrase pairing "FDA" with the product is worth reading twice. The letter makes no finding about safety, potency, or how the product was made, and the site is still trading today.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [The HCG Institute's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide. As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claims concerning compounded semaglutide products appear on your website: • “Clinically proven to reduce appetite, lower food cravings, improve food intake regulation and glycemic control.” • “Compounded Generic Semaglutide is a revolutionary FDA-inspected medication for rapid weight loss that is given once weekly.” • “All of that said, we recognize that due to American drug marketing, many people only know of semaglutide either as ‘a GLP-1’ or ‘Ozempic’ rather than by the actual name or the preferred brand name. ‘Generic’ or compounded semaglutide, like what we sell here at the HCG Institute, are the same medication, as well.”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
The HCG Institute's website was a live storefront in August 2026, titled "Buy hCG Injections Online - The HCG Institute", with a patient portal, a published phone number and a catalog spanning B12 and lipotropic injections, "GLP-1 Therapy" and "GLP-1 + GIP Therapy", sexual-health and hormone products — an operating seller. Neither "FDA-inspected" nor the word "semaglutide" appeared on the homepage; the GLP-1 categories are now named by drug class rather than by molecule.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Healthy Living Clinic
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
FDA cited a single sentence, and there is not one selling word in it: "It is also available under brand names like Wegovy, Ozempic, and Rybelsus." No superlative, no promise, no "clinically", no "FDA-approved" — it reads like a line of reference prose, which is exactly what carries it. Most letters in this round of FDA letters quote a comparison the reader could go and check; this one quotes an assumption. "Also available under" takes for granted that there is one product here going by several names, and the pronoun "It" quietly makes the compounded item in the cart that product. FDA's conclusion is its standard one: "Your claim implies that your products are the same as an FDA-approved product when they are not."
What it means for the offer
The reason to slow down on this one is that it does not sound like advertising. "It is also available under brand names like Wegovy, Ozempic, and Rybelsus" has the cadence of a footnote — the kind of neutral aside a reader files as background rather than as a pitch, and therefore does not argue with. But read who "it" is. On a page selling a compounded semaglutide subscription, the sentence says the thing in the cart is the thing sold under those three names, and it says so without ever making a comparison anyone could test. A comparison invites a check: same active ingredient as what, in what amount, made by whom. "Also available under" forecloses the question — there is nothing to compare, because it has already asserted one product with several labels. What is actually true is narrower and matters at the price: the approved products carry approved labeling, a manufacturer standing behind a specific formulation, and lot-level accountability; a compounded preparation is made for an individual by a pharmacy, has none of that paperwork behind it, and its price is set by that pharmacy rather than by the brand. So the practical test for a shopper is to ask what the seller says the product IS, in its own words, when it is not naming a brand — and to notice whether the answer names the compounding pharmacy. Checked on 2026-08-09, this company does name a specific dispensing pharmacy with an address and phone number, which is more than most sellers in this collection disclose, and the cited sentence is no longer on the semaglutide product page; the explainer paragraph it sat in remains, minus the brand names. The letter concerns wording, makes no finding about how the product was made or what is in it, and FDA has not closed it out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Healthy Living Clinic's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.
The following claim concerning compounded semaglutide products appears on your website:
• “It is also available under brand names like Wegovy, Ozempic, and Rybelsus.”
Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Healthy Living Clinic's website was live in August 2026, with a named medical director, a published helpline (1-800-599-3104), an intake quiz, and a semaglutide product page carrying a price, a strikethrough, a subscription option and a working Add to cart ($299.00 marked down to $149.00/month). This is a check of whether the site is up and what it sells; it is not a check of anything the letter alleges.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
inspire Clinic
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The three claims FDA quoted all carry a milligram figure: "Semaglutide (similar to Ozempic) 2.5 mg vial", "Tirzepatide (similar to Mounjaro) 10 mg vial" and "5 mg of semaglutide comparable to Ozempic. [sic]" — the last of which ties a specific quantity of the compounded drug to the brand rather than tying the products to each other. FDA concluded that "Your claims imply that your products are the same as an FDA-approved product when they are not." There is no label finding and no efficacy finding; the citation is confined to those three product lines.
What it means for the offer
A milligram figure changes the nature of the comparison, and this is the only letter here where one appears. "Similar to Ozempic" is a claim about a molecule; "5 mg of semaglutide comparable to Ozempic" is a claim about a dose, and dose is what you are actually buying. The two do not map onto each other. An Ozempic pen is dispensed at a weekly dose that titrates — 0.25 mg, then 0.5, then 1, then 2 — while a compounded vial is sold as a total quantity of drug that you draw from, so a "2.5 mg vial" and a "5 mg vial" are amounts of raw material, not weekly doses, and how long either lasts depends entirely on where you land in titration. This is precisely where per-month price comparisons go wrong: two sellers quoting the same monthly figure may be shipping vials that differ several-fold in total milligrams, and a vial priced against a brand tells you nothing about how many weeks it covers. The right question at checkout is total milligrams, expected weekly dose, and therefore weeks of supply — three numbers, not one. FDA's finding is about the copy alone and makes no claim about what the vials contained. The site itself is currently unreachable: the domain resolves but no Wix site is connected to it.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [inspire Clinic's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide. As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
• “Semaglutide (similar to Ozempic) 2.5 mg vial” • “Tirzepatide (similar to Mounjaro) 10 mg vial” • “5 mg of semaglutide comparable to Ozempic. [sic]”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
inspire Clinic's web address is still registered, but in August 2026 it showed only a Wix error page titled "ConnectYourDomain Error", meaning no website is connected to it. A disconnected address can be reconnected and says nothing definitive about the practice at the Grand Prairie address, so this is recorded as unknown rather than ceased-operations.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Invigorate Med Spa
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The two claims FDA quoted are product names with a brand in brackets: "Semaglutide (Wegovy)" and "Tirzepatide/B12 (Mounjaro)". The second is unlike anything else FDA cited in the letters we track — it names a combination preparation, tirzepatide with vitamin B12, and puts a single-ingredient brand-name product in the parenthesis. FDA's conclusion was the standard one, that "Compounded drug products are not FDA-approved" and the claims "imply that your products are the same as an FDA-approved product when they are not". The letter contains no label finding and no efficacy finding.
What it means for the offer
"Tirzepatide/B12 (Mounjaro)" is the most self-defeating claim in this collection, because the slash and the parenthesis contradict each other on the same line. Mounjaro contains tirzepatide and nothing else; a preparation combining tirzepatide with vitamin B12 is by definition a different product, so the bracket is inaccurate even if you grant every argument compounders make about equivalence. This matters beyond the wordplay. Adding B12 is one of the standard ways a compounded GLP-1 is made to look distinct — and, under the rules that governed compounding during the shortage, the addition of another active ingredient was part of how some sellers argued their preparation was a clinically necessary variation rather than a copy. So the same ingredient that justified compounding the product was being papered over by a brand name that does not contain it. For a buyer, the concrete question is what else is in the syringe and at what strength, because a combination product cannot be price-compared against a single-ingredient one on a per-milligram basis at all. FDA's finding is confined to the two product lines and makes no claim about the safety of either preparation. The clinic is still operating and its published menu no longer names the brands.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Invigorate Med Spa's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide. As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
“Semaglutide (Wegovy)”
“Tirzepatide/B12 (Mounjaro)”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Invigorate Med Spa's website was live in August 2026, titled "Medical Spa | InVigorate Med Spa | United States", with a full service menu covering hormone replacement, IV therapy, peptides, aesthetics and a weight-loss section, plus an online store and patient forms — an operating clinic. None of "Mounjaro", "Wegovy", "tirzepatide" or "B12" appeared in the homepage menu.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Nuvo Life Health
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Both cited claims are product names rather than sentences: "Semaglutide Injection (similar to Ozempic and Wegovy)" and "Tirzepatide (similar to Mounjaro)". The comparison sits inside the parentheses of the title itself, which means it traveled with the item — into the listing, the basket and the receipt — rather than living in body copy a reader could skip. FDA's conclusion was that "Your claims imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
Where a claim sits changes how hard it is to escape. A sentence in a FAQ can be read skeptically, or skipped. A parenthesis inside the product's own name cannot: it is what appears in the search result, on the listing, in the cart, on the confirmation email and next to the charge on the card statement. "Semaglutide Injection (similar to Ozempic and Wegovy)" is doing the job of a product title, and the job of a product title is to tell you what the thing IS. The hedge does not save it either — "similar to" is softer than "generic", but a shopper does not weigh adjectives while buying; they take the parenthesis as the explanation of what they are getting, which is precisely the point FDA made about it. The concrete habit: when the brand name is inside the product name, treat it as advertising rather than description, and go looking for the two things a title never carries — who compounded it, and what strength and formulation you are actually being sent. The site is not trading behind that domain today. The letter makes no finding about the products' quality or contents, and has not been closed out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Nuvo Life Health's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website:
• “Semaglutide Injection (similar to Ozempic and Wegovy)” • “Tirzepatide (similar to Mounjaro)”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Nuvo Life Health's website was a parked page in August 2026: a domain-parking template carrying the Sedo parking logo and ads, with no storefront behind it. A parked web address is not evidence a business has closed: it can be put back into use, and a company can trade under a different address. Recorded as unknown rather than ceased-operations.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
SemaBio
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The entire letter turns on two words. FDA quoted one claim — "generic semaglutide" — and framed it in a way it uses nowhere else in this collection: the phrase "repeatedly appears on your website". Not a headline, not a product title, but a term of art running through the catalog. FDA's conclusion is the wave's standard one: "Your claim implies that your products are the same as an FDA-approved product when they are not." No brand name was ever mentioned; "generic" did all of the work on its own.
What it means for the offer
"Generic" is the most expensive word in this collection, because it is the one shoppers already know how to price. At a pharmacy counter it means something precise and protective: an FDA-approved copy of an approved drug, shown to be therapeutically equivalent, made under the same rules, substitutable at the counter, and cheaper because the patent expired rather than because the standard dropped. Every one of those guarantees is why people relax when they read it. There is no approved generic semaglutide in the United States. So the word arriving beside a compounded product does not describe a cheaper version of the same thing — it imports a set of assurances that were never issued, and it does so in two syllables, without naming a brand or making a comparison anyone could check. That is why FDA's phrasing matters here: the claim "repeatedly appears", which is what makes it the site's vocabulary rather than a slogan someone could have removed with one edit. The domain is parked today and nothing is on sale behind it. The letter says nothing about how the products were made or what was in them, and FDA has not closed it out.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [SemaBio's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.
The following claim concerning compounded semaglutide products repeatedly appears on your website:
• “generic semaglutide”
Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
SemaBio's website was a parked page in August 2026: the address led only to a registrar's parking page, with no storefront. A parked web address is not evidence a business has closed: parking can be reversed, and a company can trade under a different address. Recorded as unknown rather than ceased-operations.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
SimpleRx
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
What FDA quoted from SimpleRx's website is not advertising copy but three product names: "Semaglutide (Ozempic)", "Tirzepatide (Zepbound)" and "Tirzepatide (generic Zepbound)". No sentence surrounds them and none was needed — FDA wrote that compounded drug products are not FDA-approved and that these claims "imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
The three things FDA cited here are not promises, arguments or adjectives — they are the names on the menu. "Tirzepatide (Zepbound)" reads as a helpful gloss, the kind of parenthetical a pharmacy might add so you know what you are looking at, and "Tirzepatide (generic Zepbound)" goes one step further into a word with a specific regulatory meaning that a compounded product does not have. That is what makes this letter useful when you are comparing prices: you can screen a site for overblown promises and still miss this, because the naming happens before any promise is made. The line item itself is doing the persuading. As for the price behind those names, the storefront was a placeholder that showed no prices when we looked, so none is listed here rather than an assumed one.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [SimpleRx's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website:
“Semaglutide (Ozempic)” “Tirzepatide (Zepbound)” “Tirzepatide (generic Zepbound)”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.
SimpleRx's website was up in August 2026, but it showed no storefront: only a holding page headed "Pardon our dust! We're working on something amazing — check back soon!" with no catalog, no prices and no mention of semaglutide or tirzepatide, and the rest of the site showed a "Database Error". That is not evidence the company has closed — a holding page can come before a relaunch — so we record this as unconfirmed rather than guessing either way.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
Vitals RX
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
The single claim FDA cited is the site’s own title line rather than any sentence of marketing copy: "Vitals RX - Semaglutide/Tirzepatide/Ozempic Weight Loss Clinic". FDA framed it with a qualifier it uses in no other letter here — the claim appears "where the only semaglutide and tirzepatide products offered are compounded" — and concluded that "Your claim implies that your products are the same as an FDA-approved product when they are not." The letter contains no label finding and no pharmacy-credential finding; listing a brand name beside the compounded ones was the whole of it.
What it means for the offer
What FDA cited here was not a promise about results — it was the shop's name. "Vitals RX - Semaglutide/Tirzepatide/Ozempic Weight Loss Clinic" reads as a description of a catalog, and it would be accurate if a brand-name product were among the things for sale. FDA's qualifier is what turns it into a claim: the only semaglutide and tirzepatide offered were compounded, so putting Ozempic in the list told a reader the compounded products were that. It is the cheapest possible version of the borrowed-credibility move, requiring no marketing copy at all, and it survives in places sales copy does not — page titles, search listings, ads. If you arrive at a storefront from a search result mentioning a brand, the thing worth checking is whether the brand is actually sold there. The separate practical point is that the domain FDA reviewed no longer resolves, and the contact domain on the letter has no registration record either. That is not proof the business has closed and we have not recorded it as such, but it does mean there is currently nothing at the address the letter names.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [Vitals RX's website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide. As described below, your claim concerning compounded semaglutide and tirzepatide products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].
The following claim appears on your website, where the only semaglutide and tirzepatide products offered are compounded: • “Vitals RX - Semaglutide/Tirzepatide/Ozempic Weight Loss Clinic”
Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
Vitals RX's website did not load in August 2026. The web address is still registered, paid up to August 2027, but the registry has put it on hold, which takes a website offline while leaving the registration intact; the address in the letter's contact email is not registered at all. A held address can be restored and a business can move, so this is recorded as unknown rather than ceased-operations.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.
ybycmeds
Read FDA’s letter →Letter issued · Status last checked · Active at that check
What FDA cited
Four product listings were quoted and all four hedge with the same two words: "Semaglutide for weight loss - Prefilled Syringes, similar to Ozempic or Wegovy", "Tirzepatide for weight loss - Prefilled Syringes, similar to Mounjaro and Zepbound", "Tirzepatide Peptide 60mg vial - similar to Mounjaro and Zepbound" and "Semaglutide Compound 10mg vial - similar to Ozempic or Wegovy". No sameness is asserted anywhere — the strongest word on the page is "similar" — and FDA still concluded that "Your claims imply that your products are the same as an FDA-approved product when they are not."
What it means for the offer
This is the useful one for anyone who assumes careful wording is a defense. Four listings, and not one of them claims the product is the same as anything — the strongest word on the page is "similar". FDA cited all four. The reason is that the finding is not about the adjective, it is about what the sentence leaves a reader believing, and "similar to Ozempic" sitting in a product title next to a price does the same work as "generic": it tells you what this is FOR by pointing at something that has been approved for it. The listings are also unusually specific in the wrong direction — "Tirzepatide Peptide 60mg vial", "Semaglutide Compound 10mg vial" — because a milligram figure attached to a vial is not the same kind of number as a dose on an approved pen, and comparing the two is how people end up comparing prices that are not comparable. What this letter does NOT do is say anything about what is in those vials, or how they were made, or whether the site's other categories are affected. It is a finding about four lines of product copy, it has not been closed out, and it is not a recall or a charge.
Quoted passages and recorded context
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address [ybycmeds' website] in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
The following claims concerning compounded semaglutide and tirzepatide products appear on your website:
• “Semaglutide for weight loss - Prefilled Syringes, similar to Ozempic or Wegovy”
• “Tirzepatide for weight loss - Prefilled Syringes, similar to Mounjaro and Zepbound”
• “Tirzepatide Peptide 60mg vial - similar to Mounjaro and Zepbound”
• “Semaglutide Compound 10mg vial - similar to Ozempic or Wegovy”
Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].
ybycmeds' website was a live storefront in August 2026, titled "YBYC - Information source for abortion and weight loss", trading as "YBYC Meds" with Women's Health and Weight Loss shop sections and a site-wide notice reading "Shipping to Alabama is restricted for certain products". That is a check of whether the site is up and what it sells; it is not a check of anything the letter alleges.
FDA response record checked : no company response was logged. That does not establish that the company did not respond.